Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, w… Read More